Efficient delivery leads to protein expression and functional outcomes from primary human blood cells.
Effective mRNA Delivery to PBMCs
PBMCs were transfected with GFP mRNA using mRNA-Fect ULTRA and compared against a leading commercial reagent. mRNA-Fect ULTRA achieved markedly higher GFP expression demonstrating superior efficiency in these hard-to-transfect immune cells.
PBMCs Secrete Functional TRAIL
PBMCs Secrete Functional TRAIL. (A) PBMCs from two donors were transfected with TRAIL mRNA using mRNA-Fect ULTRA. ELISA analysis showed strong TRAIL secretion. (B) Supernatants from the transfected PBMCs were applied to A549 cells, and viability was measured by MTT assay. Cells treated with supernatants from TRAIL mRNA–transfected PBMCs showed a clear reduction in viability compared to control mRNA, demonstrating that the secreted TRAIL proteins are biologically active.
Polymers are Biocompatible with PBMCs (Immune Safe)
PBMCs were transfected with GFP mRNA using mRNA-Fect and mRNA-Fect Kit, and a positive control (LPS). No increase in TNFa and IFNg secretion was seen, demonstrating compatibility with immune-active PBMCs.
Efficient Delivery Drives Protein Expression & Functional Outcomes
Efficient intracellular delivery is the foundation of reliable protein expression and downstream functional responses in research and therapeutic applications. Optimized delivery platforms enhance the uptake, stability, and translation of nucleic acid cargo, enabling stronger biological readouts with fewer variables. By focusing on delivery performance, scientists can achieve more consistent results across cell types and experimental systems, unlocking clearer insights into protein function, signaling pathways, and disease mechanisms.
At RJH Biosciences, we offer delivery solutions designed to maximize expression and functional activity, helping you advance projects from screening to translational impact with reproducible performance and scalable workflows.
